Stand Up To Cancer works relentlessly to offer the newest, most effective, and most promising cancer treatments to patients quickly by bringing together the best minds to collaborate, innovate, and share cancer research.
Stand Up To Cancer enables scientific breakthroughs by funding collaborative, multidisciplinary, multi-institutional scientific cancer research teams and investigators. Thanks to the support of our dedicated partners and the entertainment community, SU2C is able to bring widespread attention to cancer research and treatments.
We’re all in this together! Learn how to get involved and make a monumental impact. Join our community of passionate supporters who are committed to helping patients gain rapid access to better treatments.
Research is changing the way cancer is being treated. If you’ve been diagnosed with cancer, a clinical trial may offer access to the latest and most promising science, while helping to light the path for future survivors.
Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. We won’t stop until every cancer patient is a long-term cancer survivor.
Integrating Gnotobiotic Organoid And Metabolomic Pipelines to Prove the Cancer Microbiome Connection
SU2C Convergence 3.1416 Research Team: Integrating gnotobiotic, organoid, and metabolomic pipelines to probe the cancer-microbiome connection
January 2021-December 2023
This SU2C Convergence Research Team will study gastrointestinal malignancies using gnotobiotic assays, organoids and metabolomics in order to identify the mechanisms by which bacteria interact with host cells to cause tumor development or regression.
Epidemiological data suggest that lifestyle (including diet) and the consequent shift in the gut microbiota play a role in cancer development and therapy responsiveness. These data remain, however, largely correlative. Functional validation and molecular dissection using appropriate model systems is required. In this study, an international collaborative team from different disciplines will investigate the complex interplay between microbiota and cancer in various aspects, with an aim toward discovering the specific microorganisms and the metabolites that causally promote cancer and/or therapy responsiveness. Studies will focus largely on GI malignancies, including colorectal cancer (CRC) and pancreatic cancer (PDAC). The Team will leverage in vivo gnotobiotic pipelines, in vitro organoid systems and metabolomic expertise. Integrating the state-of-the-art gnotobiotic, organoid, and metabolomic strengths will lead to the identification of underlying mechanisms of action by which the bacterial community interacts with host cells, including epithelial cells and immune cells, to cause tumor development or trigger tumor regression.
MEET THE TEAM
The top scientists and researchers on the SU2C Convergence Research Team: Integrating gnotobiotic, organoid, and metabolomic pipelines to probe the cancer-microbiome connection come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SU2C Convergence Research Team: Integrating gnotobiotic, organoid, and metabolomic pipelines to probe the cancer-microbiome connection.